Firebrick Pharma (ASX:FRE) Total Liabilities : A$0.34 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Total Liabilities?

Firebrick Pharma's Total Liabilities for the quarter that ended in Dec. 2024 was A$0.34 Mil.

Firebrick Pharma's quarterly Total Liabilities declined from Dec. 2023 (A$0.36 Mil) to Jun. 2024 (A$0.29 Mil) but then increased from Jun. 2024 (A$0.29 Mil) to Dec. 2024 (A$0.34 Mil).

Firebrick Pharma's annual Total Liabilities increased from Jun. 2022 (A$0.45 Mil) to Jun. 2023 (A$0.51 Mil) but then declined from Jun. 2023 (A$0.51 Mil) to Jun. 2024 (A$0.29 Mil).

Firebrick Pharma Total Liabilities Historical Data

The historical data trend for Firebrick Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Total Liabilities Chart

Firebrick Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Total Liabilities

0.22

0.45

0.51

0.29

Firebrick Pharma Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial			0.50	0.51	0.36	0.29	0.34

Firebrick Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Firebrick Pharma's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.291	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	0.29

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	2.406	-	2.115
	=	0.29

Firebrick Pharma's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.338	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	0.34

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	1.835	-	1.497
	=	0.34

Firebrick Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000

Website

https://www.firebrickpharma.com

Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines